Department of Justice files suit against Johnson & Johnson in connection with kickback scheme with Omnicare

Share this article:
Most assisted living residents need meds help, survey finds
Most assisted living residents need meds help, survey finds

The U.S. Department of Justice on Friday filed a lawsuit against Johnson & Johnson for its alleged role in a kickback scheme with Omnicare, the nation's largest long-term care pharmacy chain.

Between 1999 and 2004, Johnson & Johnson allegedly paid tens of millions of dollars to nursing home pharmacy supplier Omnicare. In return, Omnicare made recommendations to hundreds of nursing home pharmacists about Johnson & Johnson-made drugs, according to the complaint. In particular, it recommended that the pharmacists prescribe the antipsychotic Risperdal. The alleged deal increased Omnicare's annual purchase of Johnson & Johnson products from $100 million to more than $280 million. It also nearly lowered the “best price” of Risperdal that Johnson & Johnson was required to report to Medicaid.

In November of 2009, Omnicare paid $98 million to the government to settle its own role in the kickback scheme. The suit was filed in a Boston federal court.
Share this article:

More in News

CMS expands therapy payment research

The government is expanding its research into alternative therapy payments, to consider more holistic changes to the way Medicare reimburses skilled nursing facilities, the Centers for Medicare & Medicaid Services announced Tuesday.

CDC tightens Ebola guidelines for healthcare workers

The Centers for Disease Control and Prevention has issued more stringent guidelines for how healthcare workers should interact with Ebola patients, following an outcry from nurses and other professionals.

Nonprofit providers face alarming market forces, must rally, LeadingAge chairman says

Nonprofit providers face alarming market forces, must rally, ...

Nonprofit long-term care providers must work together to address alarming trends, or their market share could plummet and the sector as a whole could falter, LeadingAge Chairman David Gehm told ...